Chimeric Antigen Receptor Car T Cell Immunotherapy Competitive Landscape Pipeline And Market Analysis

Overview

CAR-T cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137. A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.


“Chimeric Antigen Receptor T Cells - Competitive Landscape, Pipeline and Market Analysis, 2021” report provides comprehensive insights on the therapeutic development for this type of therapy. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Chimeric Antigen Receptor T Cells, including the marketed and pipeline products in this space. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, Chimeric Antigen Receptor T Cells licensing, deals, and other development activities is also involved in this report Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the information related to several technologies in development of the molecules based on the Chimeric Antigen Receptor T Cells mechanism. The report provides the understanding of the unmet needs of the Chimeric Antigen Receptor T Cells market.


Future competitive landscape of Chimeric Antigen Receptor T Cells is estimated to be very strong. Key emerging drugs including Celgene Corporation’s bb2121, Poseida Therapeutics’ P-BCMA-101, CD19-targeted Shanghai Ming Ju Biotechnology’s Chimeric Antigen Receptor (CAR) T Cells and others are going to be Blockbuster in the upcoming years.


Chimeric Antigen Receptor T Cells Report Key Features

The report provides insights into:

• A number of companies developing therapies of Chimeric Antigen Receptor T Cells with aggregate therapies developed by each company for the same.

• Detailed profiles of therapeutic candidates in nonclinical stage, early-stage, mid-stage and late-stage of development for Chimeric Antigen Receptor T Cells.

• Analyses key players involved in Chimeric Antigen Receptor T Cells targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Active pipeline therapies assessment under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detail analysis of collaboration (company–company collaborations and company–academia collaborations), licensing agreement and financing details for future developments of Chimeric Antigen Receptor T Cells.

• Detailed information regarding the technologies developed for the Chimeric Antigen Receptor T Cells.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.


Chimeric Antigen Receptor T Cells Analytical Perspective by DelveInsight

• In-depth Chimeric Antigen Receptor T Cells Analysis: Assessment of Products

This report provides an in-depth commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, agreements, licensing, and acquisition – deal value trends related to Chimeric Antigen Receptor T Cells. The sub-segmentation is described in the report which provides Chimeric Antigen Receptor T Cells company–company collaborations (licensing/partnering), Chimeric Antigen Receptor T Cells company–academia collaborations, and acquisition analysis in both graphical and tabulated form.

 

• Chimeric Antigen Receptor T Cells Clinical Assessment of Products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this mechanism of action.


Scope of the Report

  • The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • A detailed review of Chimeric Antigen Receptor (CAR) T cell Immunotherapy market; historical and forecasted is included in the report
  • Detailed description of the sales assessment of all the marketed drugs in CAR-T’s range
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Report Highlights

• In December 2020, Bayer and Atara Biotherapeutics, Inc. announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer


Companies Mentioned

●       Ziopharm Oncology Inc.

●       Yake Biotechnology

●       Xyphos Biosciences

●       Xi'An Yufan Biotechnology

●       Wuhan Sian Medical Technology

●       Wuhan Bio-Raid Biotechnology

●       Wugen

●       WindMIL Therapeutics

●       Wellington Zhaotai Therapies

●       VCANBIO Cell & Gene Engineering Corporation, Ltd

●       UWELL Biopharma

●       TxCell

●       Transgene

●       TrakCel

●       ToolGen

●       Tmunity Therapeutics Inc.

●       Timmune Biotech

●       TILT Biotherapeutics

●       Tianjin Mycure Medical Technology

●       The Beijing Pregene Science and Technology Company

●       Tessa Therapeutics Pte Ltd.

●       Tessa Therapeutics

●       TC BioPharm

●       Targazyme

●       Takeda / Noile-Immune Biotech

●       Takeda

●       Takara Bio

●       Synthekine

●       SymVivo

●       Sorrento Therapeutics

●       Sinobioway Cell Therapy Co., Ltd.

●       Sinobioway Cell Therapy

●       Shenzhen BinDeBio

●       Shanghai Unicar-Therapy Bio-medicine Technology

●       Shanghai Longyao Biotechnology

●       Shanghai GeneChem Co., Ltd.

●       Shanghai Biomed-union Biotechnology

●       Servier

●       Sensei Biotherapeutics

●       Sangamo

●       Sana Biotechnology

●       REGENERON

●       Protheragen

●       Pregene (ShenZhen) Biotechnology Company

●       Precision BioSciences

●       Precigen, Inc.

●       Poseida Therapeutics

●       Pfizer

●       PersonGen BioTherapeutics (Suzhou) Co., Ltd.

●       Pepromene bio

●       Oxford Biomedica

●       Obsidian Therapeutics

●       Oncternal Therapeutics

●       Novartis Pharmaceuticals

●       Noile-Immune Biotech

●       Nanjing KAEDI Biotech

●       Mustang Bio

●       MolMed

●       Minerva Biotechnologies

●       Mimivax LLC. 

●       Miltenyi Biomedicine

●       Medisix Therapeutics

●       Maxcyte

●       Marino Biotechnology Co., Ltd.

●       Liminatus Pharma

●       Kuur Therapeutics

●       Kiromic BioPharma

●       Kecellitics Biotech Company Ltd

●       Juventas Cell Therapy

●       JW Therapeutics

●       Janssen

●       Intellia Therapeutics

●       Innovative Cellular Therapeutics Co., Ltd.

●       Immunicum

●       Immuneel

●       Immune Therapeutics 

●       iCell Gene Therapeutics

●       iCarTAB BioMed

●       Hunan Zhaotai Yongren Medical Innovation

●       Humorigin

●       Humanigen

●       HRAIN Biotechnology

●       Henan Hualong Biotechnology

●       Helocyte

●       Helix BioPharma

●       Hebei Senlang Biotechnology

●       Guangzhou Bio-gene Technology Co.

And many more …


Key Questions

  • What are Chimeric Antigen Receptor T Cells, their role and significance in the treatment of disease conditions?
  • How many therapies are developed by each company for Chimeric Antigen Receptor T Cells to treat disease conditions?
  • What are the key collaborations (Industry–Industry, Industry–Academia), mergers and acquisitions, licensing activities related to the Chimeric Antigen Receptor T Cells therapies?
  • What would be the Chimeric Antigen Receptor (CAR) T cell Immunotherapy total market Size during the forecast period (2017–2030)?
  • What would be the total sales of the marketed products?
  • Which are the dormant and discontinued products and the reasons for dormancy and discontinuation?
  • What is the unmet need for current therapies developed on the basis of this mechanism of action?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chimeric Antigen Receptor T Cells and their status?
  • What are the current and upcoming technologies for the Chimeric Antigen Receptor T Cells?

1. Introduction

2. Executive Summary

3. Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Overview

4. Introduction

4.1. Structure

4.2. Mechanism

4.3. Role in Cancer therapies

4.4. Significance

4.5. Application

5. CAR-T Cell Therapy - Marketed Drugs

5.1. Kymriah: Novartis

5.1.1. Product Description

5.1.2. Product Overview

5.1.3. Mechanism of Action

5.1.4. Regulatory Milestone

5.1.5. Research and Development

5.1.6. Product Development Activities

6. CAR-T Cell Therapy – Market and Sales Assessment

7. CAR-T-Cell therapy-Commercial Analysis

7.1. Collaboration and Deals Analysis

7.2. Acquisition Analysis

7.3. Licensing Analysis

7.4. Investment Analysis

8. CAR-T Cell Therapy - Pipeline Therapeutics

8.1. Late Stage Products (Pre-Registration)

8.1.1. Idecabtagene Vicleucel: bluebird Bio

8.1.1.1. Product Description

8.1.1.2. Product Overview

8.1.1.3. Research and Development

8.1.1.4. Product Development Activities

8.1.1.5. General Description Table

Drug profiles in the detailed report…..

8.2. Mid Stage Products (Phase II)

8.2.1. TT11: Tessa Therapeutics

8.2.1.1. Product Description

8.2.1.2. Product Overview

8.2.1.3. Research and Development

8.2.1.4. Product Development Activities

8.2.1.5. General Description Table

Drug profiles in the detailed report…..

8.3. Early Stage Products (Phase I/II and Phase I)

8.3.1. Orvacabtagene autoleucel - Juno Therapeutics

8.3.1.1. Product Description

8.3.1.2. Product Overview

8.3.1.3. Research and Development

8.3.1.4. Product Development Activities

8.3.1.5. General Description Table

Drug profiles in the detailed report…..

8.3.2. CTX101: CRISPR Therapeutics

8.3.2.1. Product Description

8.3.2.2. Product Overview

8.3.2.3. Research and Development

8.3.2.4. Product Development Activities

8.3.2.5. General Description Table

9. Therapeutic Assessment

9.1. Assessment by Type of Cancer (Hematological or Solid tumor)

9.2. Assessment by Stage and Type of Cancer (Hematological or Solid tumor)

9.3. Assessment by Route of Administration

9.4. Assessment by Stage and Route of Administration

9.5. Assessment by Molecule Type

9.6. Assessment by Stage and Molecule Type

9.7. Assessment by Target

9.8. Assessment by Stage and Target

9.9. Assessment by Mechanism of Action

9.10.Assessment by Stage and Mechanism of Action

10. Inactive Products

10.1.Comparative Analysis

11. Unmet Needs

12. Market Barrier

13. Market Driver

14. References

15. Appendix

15.1.Report Methodology

16. About DelveInsight

Table 1 Assessment Summary

Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis

Table 3 Chimeric Antigen Receptor T Cells Acquisition Analysis

Table 4 Assessment by Phase of Development

Table 5 Assessment by Product Type (Mono/Combination)

Table 6 Assessment by Stage and Product Type

Table 7 Assessment by Route of Administration

Table 8 Assessment by Stage and Route of Administration

Table 9 Assessment by Molecule Type

Table 10 Assessment by Stage and Molecule Type

Table 11 Assessment by MOA

Table 12 Assessment by Stage and MOA

Table 13 Assessment by Target

Table 14 Assessment by Stage and Target

Table 15 Late-Stage Products (Phase-III)

Table 16 Mid-Stage Products (Phase-II)

Table 17 Early-Stage Products (Phase-I)

Table 18 Preclinical and Discovery Stage Products

Table 19 Inactive Products

Table 20 Dormant Products

Table 21 Discontinued Products 

Figure 1 Chimeric Antigen Receptor T Cells Structure

Figure 2 Chimeric Antigen Receptor T Cells Mechanism

Figure 3 Chimeric Antigen Receptor T Cells Types

Figure 4 Chimeric Antigen Receptor T Cells Clinical Significance

Figure 5 Chimeric Antigen Receptor T Cells companies collaborations, Licensing, Acquisition – Deal Value Trends

Figure 6 Company–Company Collaborations (Licensing/Partnering) Analysis

Figure 7 Chimeric Antigen Receptor T Cells Acquisition Analysis

Figure 8 Assessment by Phase of Development

Figure 9 Assessment by Product Type (Mono/Combination)

Figure 10 Assessment by Stage and Product Type

Figure 11 Assessment by Route of Administration

Figure 12 Assessment by Stage and Route of Administration

Figure 13 Assessment by Molecule Type

Figure 14 Assessment by Stage and Molecule Type

Figure 15 Assessment by MOA

Figure 16 Assessment by Stage and MOA

Figure 17 Late-Stage Products (Phase-III)

Figure 18 Mid-Stage Products (Phase-II)

Figure 19 Early-Stage Products (Phase-I)

Figure 20 Preclinical and Discovery Stage Products

Figure 21 Inactive Products

Figure 22 Dormant Products

Figure 23 Discontinued Products

Figure 24 Unmet Needs

  • Ziopharm Oncology Inc.
  • Yake Biotechnology
  • Xyphos Biosciences
  • Xi'An Yufan Biotechnology
  • Wuhan Sian Medical Technology
  • Wuhan Bio-Raid Biotechnology
  • Wugen
  • WindMIL Therapeutics
  • Wellington Zhaotai Therapies
  • VCANBIO Cell & Gene Engineering Corporation, Ltd
  • UWELL Biopharma
  • TxCell
  • Transgene
  • TrakCel
  • ToolGen
  • Tmunity Therapeutics Inc.
  • Timmune Biotech
  • TILT Biotherapeutics
  • Tianjin Mycure Medical Technology
  • The Beijing Pregene Science and Technology Company
  • Tessa Therapeutics Pte Ltd.
  • Tessa Therapeutics
  • TC BioPharm
  • Targazyme
  • Takeda / Noile-Immune Biotech
  • Takeda
  • Takara Bio
  • Synthekine
  • SymVivo
  • Sorrento Therapeutics
  • Sinobioway Cell Therapy Co., Ltd.
  • Sinobioway Cell Therapy
  • Shenzhen BinDeBio
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shanghai Longyao Biotechnology
  • Shanghai GeneChem Co., Ltd.
  • Shanghai Biomed-union Biotechnology
  • Servier
  • Sensei Biotherapeutics
  • Sangamo
  • Sana Biotechnology
  • REGENERON
  • Protheragen
  • Pregene (ShenZhen) Biotechnology Company
  • Precision BioSciences
  • Precigen, Inc.
  • Poseida Therapeutics
  • Pfizer
  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.
  • Pepromene bio
  • Oxford Biomedica
  • Obsidian Therapeutics
  • Oncternal Therapeutics
  • Novartis Pharmaceuticals
  • Noile-Immune Biotech
  • Nanjing KAEDI Biotech
  • Mustang Bio
  • MolMed
  • Minerva Biotechnologies
  • Mimivax LLC.
  • Miltenyi Biomedicine
  • Medisix Therapeutics
  • Maxcyte
  • Marino Biotechnology Co., Ltd.
  • Liminatus Pharma
  • Kuur Therapeutics
  • Kiromic BioPharma
  • Kecellitics Biotech Company Ltd
  • Juventas Cell Therapy
  • JW Therapeutics
  • Janssen
  • Intellia Therapeutics
  • Innovative Cellular Therapeutics Co., Ltd.
  • Immunicum
  • Immuneel
  • Immune Therapeutics
  • iCell Gene Therapeutics
  • iCarTAB BioMed
  • Hunan Zhaotai Yongren Medical Innovation
  • Humorigin
  • Humanigen
  • HRAIN Biotechnology
  • Henan Hualong Biotechnology
  • Helocyte
  • Helix BioPharma
  • Hebei Senlang Biotechnology
  • Guangzhou Bio-gene Technology Co.
  • And many more …
  • Tags:
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells p...
  • Chimeric Antigen Receptor T Cells t...
  • Chimeric Antigen Receptor T Cells d...
  • Chimeric Antigen Receptor T Cells s...
  • Chimeric Antigen Receptor T Cells m...
  • Chimeric Antigen Receptor T Cells d...
  • Chimeric Antigen Receptor T Cells e...

Forward to Friend

Need A Quote